156 related articles for article (PubMed ID: 27000280)
1. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment.
Clemmons AB; Anderegg S
J Oncol Pharm Pract; 2017 Jul; 23(5):384-388. PubMed ID: 27000280
[TBL] [Abstract][Full Text] [Related]
2. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
3. Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.
Beaven AW; Moore DT; Sharf A; Serody JS; Shea TC; Gabriel DA
Cancer Invest; 2011 Mar; 29(3):214-9. PubMed ID: 21314330
[TBL] [Abstract][Full Text] [Related]
4. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma.
Jagannath S; Vesole DH; Zhang M; Desikan KR; Copeland N; Jagannath M; Bracy D; Jones R; Crowley J; Tricot G; Barlogie B
Bone Marrow Transplant; 1997 Sep; 20(6):445-50. PubMed ID: 9313876
[TBL] [Abstract][Full Text] [Related]
5. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
Radujkovic A; Hundemer M; Eisenbach C; Luft T; Penzel R; Goldschmidt H; Ho AD; Bellos F
Leuk Lymphoma; 2014 Dec; 55(12):2967-9. PubMed ID: 24707945
[No Abstract] [Full Text] [Related]
6. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma.
Talamo G; Rakszawski KL; Rybka WB; Dolloff NG; Malysz J; Berno T; Zangari M
Eur J Haematol; 2012 Aug; 89(2):145-50. PubMed ID: 22540279
[TBL] [Abstract][Full Text] [Related]
7. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
8. Reduced charges and costs associated with outpatient autologous stem cell transplantation.
Meisenberg BR; Ferran K; Hollenbach K; Brehm T; Jollon J; Piro LD
Bone Marrow Transplant; 1998 May; 21(9):927-32. PubMed ID: 9613786
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.
Lisenko K; Sauer S; Bruckner T; Egerer G; Goldschmidt H; Hillengass J; Schmier JW; Shah S; Witzens-Harig M; Ho AD; Wuchter P
BMC Cancer; 2017 Feb; 17(1):151. PubMed ID: 28228122
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
11. Pilot Trial of Homebound Hematopoietic Cell Transplantation.
Landau HJ; Orlando E; Rodriguez ES; Applebaum A; Mitchell HR; Peled JU; Khan N; Funnell T; Chung D; Scordo M; Shah GL; LeStrange NJ; Hambright KA; McElrath CM; Cazeau N; Devlin SM; Perales MA; Giralt SA
Transplant Cell Ther; 2022 Dec; 28(12):832.e1-832.e7. PubMed ID: 36182105
[TBL] [Abstract][Full Text] [Related]
12. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
Chen J; Seabrook J; Fulford A; Rajakumar I
J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
[TBL] [Abstract][Full Text] [Related]
13. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
van Agthoven M; Segeren CM; Buijt I; Uyl-de Groot CA; van der Holt B; Lokhorst HM; Sonneveld P
Eur J Cancer; 2004 May; 40(8):1159-69. PubMed ID: 15110879
[TBL] [Abstract][Full Text] [Related]
14. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
15. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
16. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.
Martino M; Console G; Russo L; Meliado' A; Meliambro N; Moscato T; Irrera G; Messina G; Pontari A; Morabito F
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):506-512. PubMed ID: 28647402
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma.
Parmar SR; Bookout R; Shapiro JF; Tombleson R; Perkins J; Kim J; Yue B; Tomblyn M; Alsina M; Nishihori T
Bone Marrow Transplant; 2014 Jun; 49(6):761-6. PubMed ID: 24662419
[TBL] [Abstract][Full Text] [Related]
19. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the adverse effects of melphalan formulations.
Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
